title: Immune cells from SR/CR mice induce the regression of established tumors in BALB/c and C57BL/6 mice.
abstract: Few experimental models are available for the study of natural resistance to cancer. One of them is the SR/CR (spontaneous regression/complete resistance) mouse model in which natural resistance to a variety of cancer types appeared to be inherited in SR/CR strains of BALB/c and C57BL/6 mice. The genetic, cellular, and molecular effector mechanisms in this model are largely unknown, but cells from the innate immune system may play a significant role. In contrast to previous observations, the cancer resistance was limited to S180 sarcoma cancer cells. We were unable to confirm previous observations of resistance to EL-4 lymphoma cells and J774A.1 monocyte-macrophage cancer cells. The cancer resistance against S180 sarcoma cells could be transferred to susceptible non-resistant BALB/c mice as well as C57BL/6 mice after depletion of both CD4+/CD8+ leukocytes and B-cells from SR/CR mice. In the responding recipient mice, the cancer disappeared gradually following infiltration of a large number of polymorphonuclear granulocytes and remarkably few lymphocytes in the remaining tumor tissues. This study confirmed that the in vivo growth and spread of cancer cells depend on a complex interplay between the cancer cells and the host organism. Here, hereditary components of the immune system, most likely the innate part, played a crucial role in this interplay and lead to resistance to a single experimental cancer type. The fact that leukocytes depleted of both CD4+/CD8+ and B cells from the cancer resistant donor mice could be transferred to inhibit S180 cancer cell growth in susceptible recipient mice support the vision of an efficient and adverse event free immunotherapy in future selected cancer types.
authors.affiliation: Department of Experimental Medicine, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark. jako@sund.ku.dk
authors.forename: Janne
authors.initials: J
authors.lastname: Koch
authors.forename: Jann
authors.initials: J
authors.lastname: Hau
authors.forename: Jan
authors.initials: J
authors.lastname: Pravsgaard Christensen
authors.forename: Henrik
authors.initials: H
authors.lastname: Elvang Jensen
authors.forename: Morten
authors.initials: M
authors.lastname: Bagge Hansen
authors.forename: Klaus
authors.initials: K
authors.lastname: Rieneck
mesh_terms: D000818:Animals; D001402:B-Lymphocytes / Q000276:immunology; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D045744:Cell Line, Tumor; D004198:Disease Susceptibility / Q000276:immunology*; D019008:Drug Resistance, Neoplasm / Q000276:immunology; D005434:Flow Cytometry; D008214:Lymphocytes / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D009369:Neoplasms / Q000276:immunology*; D009195:Peroxidase / Q000378:metabolism
chemical_list: D009195:Peroxidase
references.citation: Vet Immunol Immunopathol. 1992 Jan 31;30(4):385-98
references.pmid: 1546443
references.citation: In Vivo. 2008 Sep-Oct;22(5):565-9
references.pmid: 18853747
references.citation: Cancer Immun. 2006 Oct 31;6:11
references.pmid: 17073402
references.citation: Cancer Immunol Immunother. 2011 Mar;60(3):319-26
references.pmid: 21267721
references.citation: Vaccine. 2009 Jan 22;27(4):558-64
references.pmid: 19027812
references.citation: BMC Cancer. 2010 May 03;10:179
references.pmid: 20438640
references.citation: Proc Natl Acad Sci U S A. 2006 May 16;103(20):7753-8
references.pmid: 16682640
references.citation: Immunogenetics. 1992;36(4):219-23
references.pmid: 1639440
references.citation: Proc Natl Acad Sci U S A. 2003 May 27;100(11):6682-7
references.pmid: 12724523
references.citation: Eur J Immunol. 1990 Dec;20(12):2747-55
references.pmid: 1980112
references.citation: Cell. 2011 Mar 4;144(5):646-74
references.pmid: 21376230
references.citation: Infect Immun. 2005 Apr;73(4):1907-16
references.pmid: 15784530
references.citation: Nature. 1984 Dec 6-12;312(5994):548-51
references.pmid: 6150440
references.citation: APMIS. 2012 Dec;120(12):974-87
references.pmid: 23030360